Given that overactivation of the phosphatidylinositol 3 kinase (PI3K)/AKT and MAPK pathways is a well-recognized trait in cancer, heightened suppression of these signaling routes represents an attractive approach to strengthen regorafenib properties. Here, AKT1 is linked to cancer.